PMSF Clinical Trials

Size	Price	Qty
50mg	USD 147
1g	USD 670

Clinical Trials

Several clinical trials have evaluated PMSF-associated parameters and outcomes in surgical and critical care settings, focusing on conditions such as cardiac surgery, valve replacement, coronary artery bypass, peri-operative fluid management, and sepsis. Sponsored predominantly by academic and hospital centers—including University Hospital Strasbourg and St George's University of London—these studies utilize non-interventional or not applicable phase classifications, with recruitment statuses ranging from completed to unknown. Overall, this body of research highlights hemodynamic monitoring and fluid responsiveness in critical care and cardiovascular surgery.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04062786	Unknown status	Scheduled Heart Surgery\|Valve Replacement\|Coronary Artery Bypass	University Hospital Strasbourg France	2019-02-21	--
NCT03300323	Unknown status	Peri-operative Fluid Management	St George''s Healthcare NHS Trust	2017-10	Not Applicable
NCT02447042	COMPLETED	Sepsis	St George's, University of London	2014-11
NCT02569008	COMPLETED	Post Cardiac Surgery	St George's, University of London	2014-01
NCT02569008	Completed	Post Cardiac Surgery	St George''s University of London	2014-01	Not Applicable

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the PMSF product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

PMSF covalently binds to and irreversibly inhibits active-site serine and cysteine proteases, thereby blocking downstream enzymatic cleavage, acetylcholinesterase activity, and anandamide degradation. This cellular inhibition stabilizes extracellular glutamate levels and modulates lipid signaling, offering potential therapeutic utility in mitigating ischemic damage and supporting hemodynamic stabilization in clinical conditions such as sepsis and post-cardiac surgery care.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).